Geometrical and Physical Conditions for Skyrmion Stability in a Nanowire

published_or_final_versio

Wired and Wireless Distributed e-Home Healthcare System

The proactive development in electronic health (e-health) has introduced seemingly endless number of applications such as telemedicine, electronic records, healthcare score cards, healthcare monitoring etc. Yet, these applications confront the key challenges of network dependence and medical personnel necessity, which hinders the development of universality of e-health services. To mitigate such key challenges, this chapter presents a versatile wired and wireless distributed e-home healthcare system. By exploiting the benefit of body sensor network and information communication technology, the dedicated system model methodically integrates some of the comprehensive functions such as pervasive health monitoring, remote healthcare data access, point-of-care signal interpretation and diagnosis, disease-driven uplink update and synchronization (UUS) scheme and emergency management to design a complete and independent e-home healthcare system. </jats:p

A service learning project on inter-professional collaboration to promote health and wellness in community organisations

Version of RecordPublishe

Poly[[aqua-μ6-benzene-1,2,3-tricarboxyl­ato-μ3-hydroxido-dizinc] hemihydrate]

In the title compound, {[Zn2(C9H3O6)(OH)(H2O)]·0.5H2O}n, there are three independent ZnII atoms present; two are located on special positions, viz a twofold rotation axis and an inversion centre, and the third is located in a general position. The ZnII atom on the inversion centre is six-coordinated by four O atoms from four different benzene-1,2,3-tricarboxyl­ate anions and two OH− anions. The ZnII atom located on a twofold axis is four coordinated by two O atoms from two different benzene-1,2,3-tricarboxyl­ate anions and two OH− anions. The third ZnII atom, located in a general position, is five coordinated by three O atoms from three different benzene-1,2,3-tricarboxyl­ate anions, one OH− anion and one water mol­ecule. Each benzene-1,2,3-tricarboxyl­ate anion bridges six ZnII atoms, and the OH− anion bridges three ZnII atoms, resulting in the formation of a three-dimensional framework. A series of O—H⋯O hydrogen bonds involving the benzene-1,2,3-tricarboxyl­ate anions, the OH− anion and the coordinating and the two water solvent mol­ecules further stablize the crystal structure. The two solvent water molecules show occupancies of 0.5 and 0.25

catena-Poly[(triaqua­zinc)-μ-furan-2,5-dicarboxyl­ato-κ3 O 2:O 2,O 2′]

In the crystal structure of the title compound, [Zn(C6H2O5)(H2O)3]n, an infinite chain is formed along [001] by linking of the Zn(H2O)3 entities with one carboxyl­ate group of the furan-2,5-dicarboxyl­ate ligand. Adjacent chains are linked by Owater—H⋯O hydrogen-bonding inter­actions. The Zn(H2O)3O3 polyhedron displays a distorted octa­hedral geometry with one weak Zn—Ocarboxyl­ate coordination [2.433 (8) A°] and two water mol­ecules located in axial positions. Except for one of the axial water molecules and two adjacent H atoms, the other atoms (including H atoms) possess site symmetry m

catena-Poly[(aqua­dimethano­lzinc)-μ-furan-2,5-dicarboxyl­ato-κ3 O 2:O 2,O 2′]

In the crystal structure of the title compound, [Zn(C6H2O5)(CH3OH)2(H2O)]n, an infinite chain is formed along the b axis by linking of the Zn(OH2)(CH3OH)2 unit with one carboxyl­ate group of the furan-2,5-dicarboxyl­ate ligand. The ZnII ion is in a distorted octa­hedral environment with one weak coordination [Zn—Ocarboxyl­ate = 2.565 (3) Å] and two meth­anol mol­ecules located in axial positions. In the chain, Owater—H⋯O hydrogen bonds are present, while adjacent chains are linked by Omethanol—H⋯O hydrogen bonds into a layer parallel to (10-2)

Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong

Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as ≥2 chronic conditions. We examine the potential additional risk of adverse events 28 days after the first dose of CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database with population-based vaccination records in Hong Kong, we analyze a retrospective cohort of patients with chronic conditions. Thirty adverse events of special interest according to the World Health Organization are examined. In total, 883,416 patients are included and 2,807 (0.3%) develop adverse events. Results suggest vaccinated patients have lower risks of adverse events than unvaccinated individuals, multimorbidity is associated with increased risks regardless of vaccination, and the association of vaccination with adverse events is not modified by multimorbidity. To conclude, we find no evidence that multimorbidity imposes extra risks of adverse events following Covid-19 vaccination

Global trends in symptomatic medication use against dementia in 66 countries/regions from 2008 to 2018

Background and purpose: The aim was to determine trends and patterns of symptomatic medication used against dementia in 66 countries and regions. Methods: This was a cross-sectional study that used the wholesale data from the IQVIA Multinational Integrated Data Analysis System database. Sale data for symptomatic medication against dementia from 66 countries and regions from 2008 to 2018 were analysed and stratified by income level (low/middle-income countries [LMICs], n = 27; high-income countries [HICs], n = 37; regions, n = 2). The medication use volume was estimated by defined daily dose (DDD) per 1000 inhabitants per day (World Health Organization DDD harmonized the size, strength and form of each pack and reflects average dosing). Changes in medication use over time were quantified as percentage changes in compound annual growth rates (CAGRs). Results: Total symptomatic medication against dementia sales increased from 0.85 to 1.33 DDD per 1000 inhabitants per day between 2008 and 2018 (LMICs 0.094–0.396; HICs 3.88–5.04), which is an increase of CAGR of 4.53% per year. The increase was mainly driven by the LMICs (CAGR = 15.42%) in comparison to the HICs (CAGR = 2.65%). The overall medication use from 2008 to 2018 increased for all four agents: memantine (CAGR = 8.51%), rivastigmine (CAGR = 6.91%), donepezil (CAGR = 2.72%) and galantamine (CAGR = 0.695%). In 2018, the most commonly used medication globally was donepezil, contributing to 49.8% of total use volume, followed by memantine (32.7%), rivastigmine (11.24%) and galantamine (6.36%). Conclusion: There was an increasing trend in the use of symptomatic medications against dementia globally, but the use remained low in LMICs. Interventions may be needed to support the medication use in some countries

Non-equilibrium relaxation and interface energy of the Ising model

{}From the non-equilibrium critical relaxation study of the two-dimensional Ising model, the dynamical critical exponent $z$ is estimated to be $2.165 \pm 0.010$ for this model. The relaxation in the ordered phase of this model is consistent with $\exp (-\sqrt{t/\tau })$ behavior. The interface energy of the three-dimensional Ising model is studied and the critical exponent of the correlation length $\nu$ and the critical amplitude of the surface tension $\sigma_0$ are estimated to be $0.6250\pm 0.025$ and $1.42\pm 0.04$, respectively. A dynamic Monte Carlo renormalization group method is applied to the equilibrium properties of the three-dimensional Ising model successfully.Comment: 32pages( 15 figures are not included. Their Postscript file is available. Request the author directly. ), LaTe